Bioxyne Limited officially rebranded to BLS Pharmaceuticals Limited and officially trades on the Australian Securities Exchange (ASX) under the new ticker symbol BLS. [1, 2]
The rebrand aligns the parent company with its wholly-owned subsidiary, Breathe Life Sciences (BLS), to reflect its transformation into a global pharmaceutical manufacturer. [1, 2]
Key Details of the Corporate Transition:
- Effective Date: Trading under the new ASX code BLS commenced on July 7, 2026.
- Share Consolidation: The name change was completed alongside a 10:1 share consolidation process. During this transitional period, the company temporarily traded under the code BXNDA.
- New Website: The company launched a dedicated corporate website at www.blspharma.com. [1, 2, 3]
About BLS Pharmaceuticals:
Headquartered in Sydney, Australia, BLS Pharmaceuticals is a life sciences company specializing in the development, manufacture, and commercialization of therapeutic products. Through Breathe Life Sciences, the company operates Good Manufacturing Practice (GMP) licensed facilities to produce medicinal cannabis, psilocybin, and MDMA for clinical trials, authorized prescribers, and global export markets
Headquartered in Sydney, Australia, BLS Pharmaceuticals is a life sciences company specializing in the development, manufacture, and commercialization of therapeutic products. Through Breathe Life Sciences, the company operates Good Manufacturing Practice (GMP) licensed facilities to produce medicinal cannabis, psilocybin, and MDMA for clinical trials, authorized prescribers, and global export markets
